Savara (NASDAQ:SVRA) Earns Buy Rating from Guggenheim

Savara (NASDAQ:SVRA - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at Guggenheim in a report released on Wednesday, Marketbeat.com reports. They presently have a $8.00 price target on the stock, down from their prior price target of $9.00. Guggenheim's price objective would indicate a potential upside of 257.14% from the company's previous close.

A number of other research analysts also recently issued reports on SVRA. HC Wainwright reiterated a "buy" rating and set a $6.00 price objective on shares of Savara in a report on Friday, March 28th. Wells Fargo & Company decreased their price objective on Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Wednesday. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $7.17.

Savara Stock Up 5.2%

Shares of NASDAQ:SVRA traded up $0.11 during mid-day trading on Wednesday, reaching $2.24. 2,519,272 shares of the stock were exchanged, compared to its average volume of 1,421,727. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The company has a market cap of $387.15 million, a P/E ratio of -5.21 and a beta of 0.44. Savara has a one year low of $1.89 and a one year high of $5.11. The stock's 50 day simple moving average is $2.93 and its 200-day simple moving average is $2.96.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.12). As a group, equities research analysts predict that Savara will post -0.45 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SVRA. JPMorgan Chase & Co. grew its stake in Savara by 23.9% in the third quarter. JPMorgan Chase & Co. now owns 69,490 shares of the company's stock valued at $295,000 after purchasing an additional 13,420 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Savara by 14.0% during the 4th quarter. SG Americas Securities LLC now owns 51,589 shares of the company's stock worth $158,000 after acquiring an additional 6,330 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Savara by 14.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company's stock worth $112,000 after acquiring an additional 4,732 shares during the period. Rhumbline Advisers boosted its stake in shares of Savara by 6.8% during the 4th quarter. Rhumbline Advisers now owns 141,425 shares of the company's stock worth $434,000 after acquiring an additional 9,041 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Savara by 7.6% during the 4th quarter. Bank of New York Mellon Corp now owns 253,630 shares of the company's stock worth $779,000 after acquiring an additional 17,870 shares during the period. 87.93% of the stock is currently owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.